
  
    
      
        Background_NNP
        Autoimmunity_NNP is_VBZ a_DT well-established_JJ mechanism_NN of_IN
        premature_JJ ovarian_NN failure_NN ._. [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._. It_PRP has_VBZ been_VBN
        suggested_VBN that_IN the_DT presence_NN of_IN ovarian_NN antibodies_NNS may_MD be_VB
        helpful_JJ in_IN the_DT diagnosis_NN of_IN ovarian_NN autoimmunity_NN [_NN 5_CD 6_CD ]_NN ._.
        However_RB ,_, presently_RB there_EX is_VBZ no_DT validated_JJ serum_NN marker_NN that_WDT
        can_MD establish_VB a_DT diagnosis_NN of_IN autoimmune_JJ premature_JJ ovarian_NN
        failure_NN with_IN certainty_NN [_NN 7_CD ]_NN ._. Young_NNP women_NNS can_MD experience_VB
        ovarian_NN failure_NN by_IN several_JJ mechanisms_NNS other_JJ than_IN
        autoimmunity_NN [_NN 8_CD ]_NN ._. A_DT false_JJ positive_JJ diagnostic_JJ test_NN
        indicating_VBG autoimmunity_NN as_IN the_DT mechanism_NN of_IN spontaneous_JJ
        premature_JJ ovarian_NN failure_NN could_MD put_VB young_JJ women_NNS at_IN risk_NN for_IN
        inappropriate_JJ therapy_NN ._. Such_JJ therapy_NN could_MD have_VB serious_JJ
        consequences_NNS ,_, such_JJ as_IN the_DT development_NN of_IN osteonecrosis_NNS [_NN 4_CD
        ]_NN
        Some_DT women_NNS with_IN premature_JJ ovarian_NN failure_NN have_VBP ovarian_NN
        follicles_NNS that_WDT function_NN intermittently_RB [_NN 9_CD 10_CD ]_NN ._. and_CC
        pregnancies_NNS have_VBP occurred_VBN after_IN the_DT diagnosis_NN of_IN premature_JJ
        ovarian_NN failure_NN [_NN 11_CD 12_CD 13_CD 14_CD ]_NN ._. Clinicians_NNP are_VBP in_IN need_NN of_IN
        an_DT accurate_JJ method_NN for_IN the_DT diagnosis_NN of_IN autoimmune_JJ
        oophoritis_NNS ,_, a_DT test_NN with_IN proven_VBN sensitivity_NN and_CC specificity_NN
        [_NN 15_CD ]_NN ._. Here_RB we_PRP conduct_VBP an_DT investigation_NN to_TO determine_VB
        whether_IN a_DT commercially_RB available_JJ ovarian_NN antibody_NN test_NN
        (_( Immunodiagnostic_NNP Laboratories_NNPS ,_, Inc_NNP ._. ,_, San_NNP Leandro_NNP ,_, CA_NNP )_)
        might_MD be_VB useful_JJ in_IN the_DT diagnosis_NN of_IN autoimmune_JJ premature_JJ
        ovarian_NN failure_NN ._. We_PRP performed_VBD the_DT test_NN in_IN women_NNS with_IN
        premature_JJ ovarian_NN failure_NN ,_, women_NNS with_IN normal_JJ ovarian_NN
        function_NN ,_, and_CC in_IN men_NNS ._. We_PRP found_VBD that_IN this_DT commercially_RB
        available_JJ test_NN has_VBZ a_DT high_JJ incidence_NN of_IN false_JJ positives_NNS ._.
        Therefore_RB ,_, this_DT test_NN would_MD not_RB be_VB expected_VBN to_TO be_VB useful_JJ in_IN
        the_DT diagnosis_NN of_IN autoimmune_JJ premature_JJ ovarian_NN failure_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS and_CC Controls_NNP
          By_IN local_JJ advertisement_NN we_PRP recruited_VBD 26_CD control_NN women_NNS
          with_IN regular_JJ menstrual_JJ cycles_NNS (_( matched_VBN for_IN age_NN and_CC parity_NN
          to_TO our_PRP$ patients_NNS )_) and_CC 26_CD control_NN men_NNS (_( matched_VBN for_IN age_NN )_) ._.
          The_DT controls_NNS were_VBD also_RB matched_VBN to_TO patients_NNS for_IN race_NN ._. We_PRP
          recruited_VBD patients_NNS with_IN spontaneous_JJ premature_JJ ovarian_NN
          failure_NN by_IN letters_NNS to_TO physicians_NNS and_CC notices_NNS in_IN medical_JJ
          journals_NNS ._. The_DT National_NNP Institute_NNP of_IN Child_NNP Health_NNP and_CC
          Human_NNP Development_NNP Institutional_NNP Review_NNP Board_NNP approved_VBD the_DT
          protocol_NN ._. We_PRP diagnosed_VBD premature_JJ ovarian_NN failure_NN in_IN women_NNS
          who_WP before_IN the_DT age_NN of_IN 40_CD had_VBD experienced_VBN amenorrhea_NN in_IN
          association_NN with_IN serum_NN FSH_NNP levels_NNS greater_JJR than_IN 40_CD mIU_NN /_NN mL_NN
          (_( confirmed_VBD on_IN two_CD separate_JJ occasions_NNS ,_, at_IN least_JJS one_CD month_NN
          apart_RB )_) ._. Twenty-six_NNP patients_NNS with_IN premature_JJ ovarian_NN
          failure_NN participated_VBD in_IN this_DT study_NN (_( median_JJ age_NN of_IN 33_CD
          years_NNS ,_, range_NN 18_CD -_: 39_CD years_NNS )_) ._. The_DT women_NNS had_VBD been_VBN diagnosed_VBN
          at_IN a_DT median_JJ age_NN of_IN 30_CD years_NNS (_( range_NN 15_CD -_: 38_CD years_NNS )_) ._. The_DT
          median_JJ time_NN since_IN diagnosis_NN was_VBD 2_CD years_NNS (_( range_NN 0_CD ._. 33_CD -_: 12_CD
          years_NNS )_) ._. All_DT patients_NNS had_VBD a_DT normal_JJ karyotype_NN and_CC had_VBD no_DT
          history_NN of_IN chemotherapy_NN or_CC radiation_NN ._. Six_CD patients_NNS (_( 26_CD %_NN )_)
          had_VBD hypothyroidism_NN ,_, one_CD patient_NN had_VBD Addison_NNP disease_NN ,_, and_CC
          one_CD patient_NN had_VBD Raynaud_NNP syndrome_NN ._.
        
        
          Ovarian_NNP Antibodies_NNP
          We_PRP sent_VBD blinded_JJ specimens_NNS to_TO Immunodiagnostic_NNP
          Laboratories_NNPS ,_, Inc_NNP ._. (_( San_NNP Leandro_NNP ,_, CA_NNP )_) to_TO be_VB tested_VBN for_IN
          ovarian_NN antibodies_NNS using_VBG an_DT indirect_JJ immunofluorescence_NN
          test_NN system_NN supplied_VBN by_IN Scimedx_NNP Inc_NNP ._. (_( Denville_NNP ,_, NJ_NNP )_) ._. The_DT
          kit_NN includes_VBZ frozen_VBN sections_NNS of_IN cynomologous_JJ monkey_NN ovary_JJ
          as_IN tissue_NN substrate_NN ,_, a_DT positive_JJ control_NN of_IN human_JJ serum_NN
          known_VBN to_TO contain_VB antibodies_NNS against_IN the_DT zona_NN pellucida_NN ,_, a_DT
          negative_JJ control_NN serum_NN ,_, and_CC fluorescein_NN isothiocyanate_NN
          (_( FITC_NNP )_) conjugated_JJ goat_NN antibodies_NNS against_IN human_JJ
          immunoglobulins_NNS including_VBG IgG_NNP ,_, IgM_NNP and_CC IgA_NNP ._. Binding_NNP of_IN
          antibody_NN to_TO the_DT zona_NN pellucida_NN at_IN a_DT 1_CD :_: 10_CD dilution_NN was_VBD
          reported_VBN by_IN the_DT laboratory_NN on_IN a_DT scale_NN of_IN 0_CD to_TO 3_CD +_NN
          according_VBG to_TO the_DT intensity_NN of_IN fluorescence_NN :_: 0_CD ,_, negative_JJ ;_:
          1_CD +_NN ,_, weak_JJ ;_: 2_CD +_NN moderate_JJ or_CC 3_CD +_NN strong_JJ fluorescence_NN (_( Figure_NN
          1_LS )_) ._.
          We_PRP also_RB tested_VBD serum_NN in_IN our_PRP$ own_JJ laboratory_NN using_VBG this_DT
          same_JJ test_NN system_NN (_( Scimedx_NNP ,_, Inc_NNP ._. ,_, Denville_NNP ,_, NJ_NNP )_) ._. Aliquoted_NNP
          serum_NN samples_NNS of_IN patients_NNS and_CC controls_NNS were_VBD stored_VBN at_IN
          -_: 80_CD °_NN C_NNP ._. After_IN thawing_VBG at_IN room_NN temperature_NN ,_, serum_NN samples_NNS
          were_VBD diluted_VBN 1_CD :_: 10_CD with_IN PBS_NNP ._. We_PRP confirmed_VBD the_DT adequacy_NN of_IN
          monkey_NN ovary_JJ sections_NNS from_IN individual_JJ lots_NNS in_IN an_DT
          unblinded_JJ manner_NN before_IN using_VBG them_PRP ._. For_IN each_DT experiment_NN
          slides_NNS of_IN monkey_NN ovary_JJ with_IN the_DT same_JJ lot_NN number_NN were_VBD
          allowed_VBN to_TO equilibrate_NN to_TO room_NN temperature_NN ._. Twenty_CD
          microliters_NNS of_IN blinded_JJ sample_NN were_VBD applied_VBN to_TO the_DT tissue_NN
          substrate_NN slides_NNS ._. A_DT slide_NN containing_VBG positive_JJ and_CC
          negative_JJ controls_NNS was_VBD run_VBN unblinded_JJ with_IN each_DT experiment_NN ._.
          Slides_NNS were_VBD placed_VBN into_IN a_DT moist_NN covered_VBD chamber_NN and_CC
          incubated_JJ for_IN 30_CD minutes_NNS at_IN room_NN temperature_NN ._. Next_JJ ,_, the_DT
          slides_NNS were_VBD washed_VBN in_IN PBS_NNP for_IN three_CD 10_CD -_: minute_NN soaks_NNS ._.
          After_IN blotting_VBG the_DT slides_NNS ,_, 20_CD uL_NN of_IN FITC-conjugated_NNP goat_NN
          antibodies_NNS against_IN human_JJ immunoglobulins_NNS was_VBD delivered_VBN to_TO
          each_DT sample_NN and_CC slides_NNS were_VBD again_RB incubated_JJ in_IN the_DT moist_NN
          chamber_NN for_IN 30_CD minutes_NNS ._. The_DT washings_NNS and_CC blotting_VBG were_VBD
          repeated_VBN as_IN above_IN ._. Mounting_NNP medium_NN and_CC a_DT coverslip_NN were_VBD
          applied_VBN ._. The_DT slides_NNS were_VBD kept_VBN in_IN a_DT dark_JJ moist_NN chamber_NN
          until_IN evaluated_VBN using_VBG a_DT Zeiss_NNP Axiophot_NNP Fluorescent_NNP
          Microscope_NNP (_( Carl_NNP Zeiss_NNP Inc_NNP ._. ,_, Thornwood_NNP ,_, NY_NNP )_) at_IN 40_CD ×_NN
          magnification_NN with_IN emission_NN at_IN 400_CD nM_NN and_CC excitation_NN at_IN
          520_CD -_: 560_CD nM_NN ._. We_PRP graded_JJ fluorescence_NN of_IN the_DT zona_NN pellucida_NN
          on_IN the_DT same_JJ 0_CD to_TO 3_CD +_NN scale_NN as_IN noted_VBN above_IN ._.
        
        
          Reproducibility_NNP
          To_TO evaluate_VB the_DT reproducibility_NN of_IN the_DT test_NN we_PRP
          selected_VBD four_CD patient_NN samples_NNS previously_RB determined_VBN by_IN
          this_DT technique_NN to_TO be_VB 0_CD ,_, 1_CD +_NN ,_, 2_CD +_NN ,_, and_CC 3_CD +_NN for_IN zona_NN pellucida_NN
          antibodies_NNS ._. In_IN a_DT blinded_JJ manner_NN ,_, we_PRP tested_VBD each_DT sample_NN 15_CD
          times_NNS (_( 5_CD tests_NNS each_DT on_IN three_CD separate_JJ days_NNS )_) ._.
        
        
          Other_JJ Autoantibodies_NNP
          Antinuclear_NNP antibody_NN (_( ANA_NNP )_) titer_NN was_VBD determined_VBN by_IN
          indirect_JJ immunofluorescence_NN using_VBG Hep-_NNP 2_CD substrate_NN ._.
          Rheumatoid_NNP factor_NN was_VBD determined_VBN by_IN latex_NN agglutination_NN ._.
          Antiparietal_NNP cell_NN antibodies_NNS were_VBD measured_VBN by_IN indirect_JJ
          immunofluorescence_NN using_VBG rat_NN stomach_NN (_( Smith_NNP Kline_NNP Beecham_NNP
          Clinical_NNP Laboratories_NNPS ,_, Van_NNP Nuys_NNP ,_, CA_NNP )_) ._. Antithyroid_NNP
          peroxidase_NN (_( anti-_NN TPO_NNP )_) binding_JJ activity_NN was_VBD determined_VBN by_IN
          a_DT radiobinding_VBG assay_NN using_VBG Iodine_NNP 125_CD labelled_JJ human_JJ
          recombinant_JJ thyroid_NN peroxidase_NN (_( Nichols_NNP Institute_NNP ,_, San_NNP
          Juan_NNP Capistano_NNP ,_, CA_NNP )_) ._.
        
        
          Statistics_NNS
          We_PRP used_VBD the_DT Fischer_NNP exact_JJ test_NN ,_, chi-square_JJ ,_, and_CC the_DT
          Spearman_NNP rank_NN correlation_NN test_NN as_IN appropriate_JJ ._. We_PRP used_VBD
          one-tailed_JJ tests_NNS to_TO look_VB for_IN an_DT increase_NN in_IN autoantibody_NN
          as_IN compared_VBN to_TO controls_NNS and_CC we_PRP set_VBD 
          P_NN <_NN 0_CD ._. 05_CD as_IN significant_JJ ._.
          Statistical_NNP analysis_NN was_VBD performed_VBN using_VBG Sigma_NNP Stat_NNP
          Software_NNP (_( Jandel_NNP Scientific_NNP ,_, San_NNP Rafael_NNP ,_, CA_NNP )_) ._.
        
      
      
        Results_NNS
        
          Ovarian_NNP antibodies_NNS
          
            By_IN commercial_JJ laboratory_NN
            Eight_CD of_IN 26_CD control_NN women_NNS (_( 31_CD %_NN )_) and_CC 13_CD of_IN 26_CD women_NNS
            with_IN spontaneous_JJ premature_JJ ovarian_NN failure_NN (_( 50_CD %_NN )_) had_VBD
            ovarian_NN antibodies_NNS as_IN detected_VBN by_IN the_DT commercial_JJ
            laboratory_NN (_( Table_NNP 1_LS )_) ._. The_DT frequencies_NNS were_VBD not_RB
            significantly_RB different_JJ (_( 
            P_NN =_SYM 0_CD ._. 26_CD ,_, chi-square_JJ test_NN )_) ._.
          
          
            By_IN our_PRP$ own_JJ laboratory_NN
            When_WRB we_PRP evaluated_VBD these_DT same_JJ samples_NNS for_IN ovarian_NN
            antibodies_NNS in_IN our_PRP$ own_JJ laboratory_NN we_PRP obtained_VBD similar_JJ
            results_NNS ._. Twelve_CD of_IN 26_CD patients_NNS (_( 46_CD %_NN )_) with_IN premature_JJ
            ovarian_NN failure_NN had_VBD ovarian_NN antibodies_NNS versus_CC 10_CD of_IN 26_CD
            control_NN women_NNS (_( 38_CD %_NN )_) (_( 
            P_NN =_SYM 0_CD ._. 78_CD ,_, chi-square_JJ test_NN ;_: Table_NNP
            1_LS )_) ._.
          
        
        
          Reproducibility_NNP
          We_PRP could_MD not_RB reliably_RB reproduce_VB the_DT four_CD categories_NNS of_IN
          ovarian_NN antibody_NN test_NN grading_VBG ._. Although_IN our_PRP$ results_NNS
          correlated_JJ with_IN the_DT known_VBN graded_JJ samples_NNS (_( r_LS =_SYM 0_CD ._. 72_CD ,_, 
          P_NN <_NN 0_CD ._. 05_CD )_) ,_, the_DT 1_CD +_NN readings_NNS were_VBD
          reproduced_VBD in_IN only_RB 8_CD of_IN the_DT 15_CD tests_NNS (_( 53_CD %_NN )_) and_CC the_DT 2_CD +_NN
          readings_NNS were_VBD reproduced_VBD in_IN only_RB 2_CD of_IN the_DT 15_CD tests_NNS (_( 13_CD %_NN )_)
          (_( Table_NNP 2_LS )_) ._. In_IN contrast_NN ,_, the_DT 0_CD and_CC 3_CD +_NN readings_NNS were_VBD
          reproduced_VBD in_IN 13_CD (_( 87_CD %_NN )_) and_CC 12_CD (_( 80_CD %_NN )_) of_IN the_DT 15_CD respective_JJ
          tests_NNS (_( Table_NNP 2_LS )_) ._.
        
        
          Efforts_NNS to_TO improve_VB the_DT test_NN
          Because_IN the_DT 1_CD +_NN and_CC 2_CD +_NN readings_NNS had_VBD poor_JJ
          reproducibility_NN ,_, we_PRP were_VBD concerned_VBN that_IN this_DT inaccuracy_NN
          might_MD have_VB impaired_VBN our_PRP$ ability_NN to_TO detect_VB a_DT difference_NN
          between_IN patients_NNS and_CC control_NN women_NNS ._. We_PRP therefore_RB
          redefined_VBD the_DT outcome_NN measure_NN to_TO be_VB read_VBN simply_RB as_IN
          positive_JJ (_( +_NN )_) or_CC negative_JJ (_( -_: )_) ._. Positive_JJ was_VBD defined_VBN as_IN the_DT
          presence_NN of_IN homogeneous_JJ fluorescence_NN on_IN the_DT zona_NN
          pellucida_NN above_IN background_NN and_CC negative_NN was_VBD defined_VBN as_IN
          any_DT fluorescence_NN less_JJR than_IN this_DT ._. Tests_NNP were_VBD then_RB repeated_VBN
          using_VBG serum_NN from_IN the_DT 26_CD patients_NNS and_CC 26_CD control_NN women_NNS ._. We_PRP
          were_VBD unable_JJ to_TO demonstrate_VB a_DT significant_JJ difference_NN using_VBG
          the_DT revised_VBN outcome_NN measure_NN ._. Patient_NNP serum_NN was_VBD positive_JJ
          in_IN 14_CD of_IN 26_CD samples_NNS (_( 54_CD %_NN )_) and_CC control_NN serum_NN was_VBD positive_JJ
          in_IN 11_CD of_IN 26_CD samples_NNS (_( 42_CD %_NN )_) (_( Table_NNP 1_LS )_) ._. When_WRB we_PRP tested_VBD the_DT
          sera_NN on_IN three_CD separate_JJ occasions_NNS with_IN this_DT method_NN ,_, we_PRP
          found_VBD 9_CD patient_NN sera_NN (_( 35_CD %_NN )_) and_CC 6_CD control_NN sera_NN (_( 23_CD %_NN )_) to_TO be_VB
          consistently_RB positive_JJ for_IN zona_NN pellucida_NN antibody_NN (_( 
          P_NN =_SYM 0_CD ._. 38_CD )_) ._.
          We_PRP were_VBD unable_JJ to_TO improve_VB the_DT test_NN by_IN using_VBG higher_JJR
          dilutions_NNS of_IN serum_NN (_( 1_CD :_: 20_CD ,_, 1_CD :_: 40_CD ,_, and_CC 1_CD :_: 80_CD )_) ._. All_DT 26_CD
          patients_NNS and_CC all_DT 26_CD controls_NNS were_VBD negative_JJ for_IN ovarian_NN
          antibodies_NNS at_IN 1_CD :_: 20_CD ._. The_DT positive_JJ control_NN sample_NN was_VBD
          positive_JJ at_IN 1_CD :_: 40_CD and_CC negative_JJ at_IN 1_CD :_: 80_CD ._.
        
        
          Specificity_NNP
          To_TO evaluate_VB the_DT specificity_NN of_IN the_DT test_NN we_PRP compared_VBD
          sera_NN from_IN 26_CD normal_JJ women_NNS with_IN sera_NN from_IN 26_CD normal_JJ men_NNS
          matched_VBN for_IN age_NN ._. The_DT tests_NNS were_VBD performed_VBN at_IN 1_CD :_: 10_CD
          dilution_NN using_VBG the_DT positive_JJ and_CC negative_JJ outcome_NN measure_NN
          as_IN discussed_VBN above_IN ._. Women_NNP were_VBD significantly_RB more_RBR likely_JJ
          to_TO have_VB ovarian_NN antibodies_NNS than_IN men_NNS ._. Eleven_CD of_IN 26_CD normal_JJ
          women_NNS (_( 42_CD %_NN )_) had_VBD ovarian_NN antibodies_NNS whereas_IN none_NN of_IN the_DT 26_CD
          normal_JJ men_NNS had_VBD these_DT antibodies_NNS (_( 
          P_NN <_NN 0_CD ._. 001_CD )_) ._. These_DT findings_NNS were_VBD
          confirmed_VBN in_IN a_DT separate_JJ experiment_NN (_( 9_CD /_NN 26_CD versus_CC 0_CD /_NN 26_CD ,_, 
          P_NN <_NN 0_CD ._. 002_CD )_) ._.
        
        
          Other_JJ Auto-antibodies_NNP
          Results_NNS of_IN other_JJ antibody_NN tests_NNS are_VBP shown_VBN in_IN Table_NNP 3_CD ._.
          Women_NNP with_IN spontaneous_JJ premature_JJ ovarian_NN failure_NN were_VBD
          significantly_RB more_RBR likely_JJ than_IN control_NN women_NNS to_TO have_VB
          parietal_NN cell_NN antibodies_NNS (_( 
          P_NN <_NN 0_CD ._. 05_CD ,_, Fischer_NNP 's_POS exact_JJ test_NN )_)
          and_CC thyroid_NN peroxidase_NN antibodies_NNS (_( 
          P_NN <_NN 0_CD ._. 05_CD ,_, Fischer_NNP 's_POS exact_JJ
          test_NN )_) ._.
        
      
      
        Discussion_NNP
        There_EX is_VBZ evidence_NN to_TO suggest_VB that_IN some_DT patients_NNS with_IN
        spontaneous_JJ premature_JJ ovarian_NN may_MD have_VB clinically_RB
        significant_JJ circulating_VBG ovarian_NN antibodies_NNS ._. In_IN a_DT seminal_NN
        study_NN reported_VBD in_IN 1979_CD ,_, Coulam_NNP and_CC Ryan_NNP demonstrated_VBD that_IN
        patients_NNS with_IN premature_JJ ovarian_NN failure_NN ,_, as_IN a_DT group_NN ,_, have_VBP
        ovarian_NN antibodies_NNS present_JJ in_IN their_PRP$ sera_NN as_IN determined_VBN by_IN
        immunoprecipitation_NN of_IN radiolabeled_JJ human_JJ ovarian_NN proteins_NNS
        [_NN 16_CD ]_NN ._. However_RB ,_, the_DT identity_NN of_IN these_DT specific_JJ ovarian_NN
        antigen_NN (_( s_VBZ )_) remains_VBZ unknown_JJ ._. It_PRP should_MD pointed_VBD out_IN ,_, however_RB ,_,
        that_IN immunoblotting_VBG studies_NNS have_VBP failed_VBN to_TO reveal_VB a_DT
        consistent_JJ pattern_NN of_IN binding_VBG using_VBG the_DT sera_NN of_IN patients_NNS
        with_IN premature_JJ ovarian_NN failure_NN [_NN 7_CD ]_NN ._.
        Presently_NNP ,_, there_EX is_VBZ no_DT proven_VBN sensitive_JJ and_CC specific_JJ
        serum_NN test_NN to_TO confirm_VB that_IN a_DT woman_NN has_VBZ ovarian_NN failure_NN on_IN
        an_DT autoimmune_JJ basis_NN [_NN 7_CD ]_NN ._. Histologic_NNP evaluation_NN of_IN the_DT
        ovary_JJ is_VBZ the_DT only_JJ way_NN to_TO diagnose_NN autoimmune_JJ oophoritis_NNS
        with_IN certainty_NN [_NN 17_CD ]_NN ._. Nonetheless_RB ,_, some_DT clinicians_NNS
        currently_RB use_VBP commercial_JJ ovarian_NN antibody_NN tests_NNS for_IN the_DT
        diagnosis_NN of_IN autoimmune_JJ premature_JJ ovarian_NN failure_NN and_CC make_VB
        treatment_NN recommendations_NNS based_VBN on_IN these_DT findings_NNS ._. This_DT
        approach_NN can_MD have_VB severe_JJ adverse_JJ consequences_NNS such_JJ as_IN the_DT
        development_NN of_IN osteonecrosis_NNS related_VBN to_TO glucocorticoid_NN
        therapy_NN [_NN 4_CD ]_NN ._. Here_RB we_PRP demonstrate_VBP that_DT detection_NN of_IN
        ovarian_NN antibodies_NNS by_IN indirect_JJ immunofluorescence_NN using_VBG one_CD
        specific_JJ commercial_JJ test_NN system_NN has_VBZ poor_JJ specificity_NN as_IN a_DT
        diagnostic_JJ test_NN ._. The_DT test_NN is_VBZ positive_JJ in_IN nearly_RB one-third_NN
        of_IN normal_JJ women_NNS ._. Therefore_RB ,_, the_DT test_NN is_VBZ not_RB a_DT useful_JJ
        diagnostic_JJ marker_NN of_IN autoimmune_JJ premature_JJ ovarian_NN
        failure_NN ._.
        We_PRP found_VBD that_IN women_NNS with_IN premature_JJ ovarian_NN failure_NN are_VBP
        significantly_RB more_RBR likely_JJ to_TO have_VB positive_JJ thyroid_NN
        peroxidase_NN and_CC parietal_NN cell_NN autoantibodies_NNS than_IN women_NNS with_IN
        normal_JJ ovarian_NN function_NN ._. In_IN this_DT regard_NN our_PRP$ findings_NNS are_VBP in_IN
        agreement_NN with_IN previous_JJ studies_NNS [_NN 18_CD 19_CD 20_CD ]_NN ._. In_IN contrast_NN
        to_TO one_CD previous_JJ study_NN ,_, however_RB [_NN 21_CD ]_NN ,_, we_PRP did_VBD not_RB find_VB a_DT
        significantly_RB higher_JJR prevalence_NN of_IN antinuclear_NN antibodies_NNS
        in_IN women_NNS with_IN premature_JJ ovarian_NN failure_NN ._.
        Because_IN little_JJ is_VBZ known_VBN about_IN the_DT pathophysiology_NN of_IN
        human_JJ autoimmune_JJ oophoritis_NNS ,_, experimental_JJ animal_NN models_NNS
        have_VBP been_VBN used_VBN to_TO gain_VB insight_NN into_IN possible_JJ mechanisms_NNS [_NN
        22_CD 23_CD ]_NN ._. The_DT fact_NN that_IN we_PRP found_VBD an_DT increased_VBN frequency_NN of_IN
        thyroid_NN and_CC gastric_JJ parietal_NN cell_NN antibodies_NNS in_IN our_PRP$
        patients_NNS suggests_VBZ similarity_NN to_TO a_DT model_NN of_IN autoimmune_JJ
        ovarian_NN failure_NN that_WDT can_MD be_VB induced_VBN in_IN certain_JJ strains_NNS of_IN
        mice_NNS by_IN performing_VBG neonatal_NN thymectomy_NN ._. These_DT mice_NNS also_RB
        develop_VBP autoimmunity_NN against_IN thyroid_NN and_CC gastric_JJ parietal_NN
        cells_NNS [_NN 22_CD ]_NN ._. It_PRP is_VBZ well_RB established_VBN that_IN these_DT mice_NNS with_IN
        ovarian_NN autoimmunity_NN also_RB develop_VB circulating_VBG
        autoantibodies_NNS against_IN the_DT oocyte_NN cytoplasm_NN ,_, the_DT zona_NN
        pellucida_NN ,_, and_CC against_IN steroid_NN producing_VBG cells_NNS [_NN 22_CD ]_NN ._.
        While_IN we_PRP found_VBD evidence_NN that_IN one_CD half_NN of_IN our_PRP$ patients_NNS had_VBD
        specific_JJ antibodies_NNS directed_VBN against_IN the_DT zona_NN pellucida_NN ,_, we_PRP
        did_VBD not_RB find_VB any_DT consistent_JJ pattern_NN of_IN immunofluorescence_NN
        to_TO suggest_VB that_IN our_PRP$ patients_NNS had_VBD antibodies_NNS directed_VBN
        against_IN the_DT oocyte_NN cytoplasm_NN or_CC the_DT steroid_NN producing_VBG cells_NNS
        of_IN the_DT ovary_JJ ._. It_PRP is_VBZ noteworthy_JJ that_IN immune_JJ serum_NN from_IN mice_NNS
        with_IN ovarian_NN autoimmunity_NN reacts_VBZ specifically_RB with_IN an_DT
        oocyte-specific_JJ protein_NN called_VBD MATER_NNP [_NN 24_CD 25_CD ]_NN ._. We_PRP have_VBP
        subsequently_RB identified_VBN the_DT homologous_RB human_JJ 
        MATER_NNP gene_NN and_CC protein_NN [_NN 26_CD ]_NN In_IN
        ongoing_JJ work_NN we_PRP are_VBP evaluating_VBG the_DT value_NN of_IN MATER_NNP
        antibodies_NNS as_IN a_DT marker_NN for_IN autoimmune_JJ ovarian_NN failure_NN in_IN
        women_NNS ._.
        The_DT fact_NN that_IN we_PRP did_VBD not_RB detect_VB ovarian_NN antibodies_NNS
        binding_VBG to_TO the_DT zona_NN pellucida_NN in_IN any_DT of_IN 26_CD men_NNS (_( p_NN <_NN
        0_CD ._. 001_CD )_) is_VBZ intriguing_JJ ._. This_DT finding_VBG supports_VBZ proposals_NNS that_WDT
        pre-_NN B_NNP cells_NNS undergo_VBP positive_JJ selection_NN directed_VBN by_IN the_DT
        presence_NN of_IN surface_NN heavy_JJ chains_NNS with_IN low_JJ albeit_IN sufficient_JJ
        affinity_NN to_TO the_DT autoantigen_NN ._. It_PRP appears_VBZ then_RB ,_, that_IN men_NNS ,_,
        lacking_VBG the_DT specific_JJ ovarian_NN self-antigen_JJ ,_, fail_VB to_TO provide_VB
        positive_JJ selection_NN for_IN these_DT pre-_NN B_NNP cells_NNS clones_NNS ._. Also_RB ,_, this_DT
        finding_VBG suggests_VBZ that_IN the_DT detection_NN system_NN is_VBZ specific_JJ for_IN
        zona_NN pellucida_NN ,_, and_CC that_IN further_JJ refinement_NN of_IN the_DT assay_NN
        system_NN by_IN using_VBG pure_JJ human_JJ recombinant_JJ zona_NN pellucida_NN
        protein_NN might_MD be_VB useful_JJ ._. Sacco_NNP and_CC Moghissi_NNP detected_VBD zona_NN
        pellucida_NN antibodies_NNS in_IN both_DT men_NNS and_CC women_NNS by_IN indirect_JJ
        immunofluorescence_NN ,_, but_CC they_PRP used_VBD porcine_NN rather_RB than_IN
        primate_NN zonae_NN pellicidae_NN [_NN 27_CD ]_NN ._. Normal_NNP animal_NN and_CC human_JJ
        serum_NN are_VBP known_VBN to_TO contain_VB a_DT wide_JJ range_NN of_IN low-titer_JJ
        autoantibodies_NNS that_WDT have_VBP been_VBN termed_VBN "_'' natural_JJ
        autoantibodies_NNS "_'' [_NN 28_CD ]_NN ._. Even_RB B_NNP cells_NNS from_IN newborn_JJ mice_NNS and_CC
        human_JJ cord_NN blood_NN produce_VBP these_DT natural_JJ autoantibodies_NNS [_NN 29_CD
        30_CD 31_CD ]_NN ._. The_DT low_JJ titer_NN ovarian_NN antibodies_NNS that_IN we_PRP
        demonstrate_VBP here_RB in_IN the_DT serum_NN of_IN normal_JJ women_NNS are_VBP likely_JJ
        natural_JJ autoantibodies_NNS ,_, and_CC not_RB antibodies_NNS with_IN any_DT
        pathophysiologic_JJ significance_NN ._.
        Identifying_NNP women_NNS with_IN autoimmune_JJ premature_JJ ovarian_NN
        failure_NN presents_VBZ the_DT opportunity_NN to_TO restore_VB ovarian_NN
        function_NN by_IN proper_JJ immune_JJ modulation_NN therapy_NN ._. However_RB ,_, at_IN
        present_JJ we_PRP do_VBP n't_RB really_RB know_VB how_WRB many_JJ women_NNS with_IN premature_JJ
        ovarian_NN failure_NN develop_VB it_PRP due_JJ to_TO autoimmunity_NN ._. Currently_RB ,_,
        ovarian_NN biopsy_NN is_VBZ the_DT only_JJ way_NN to_TO diagnose_NN autoimmune_JJ
        premature_JJ ovarian_NN failure_NN with_IN certainty_NN ._. However_RB ,_, because_IN
        there_EX is_VBZ no_DT treatment_NN proven_VBN safe_JJ and_CC effective_JJ to_TO restore_VB
        fertility_NN ,_, in_IN our_PRP$ view_NN ,_, ovarian_NN biopsy_NN is_VBZ not_RB indicated_VBN
        outside_IN a_DT controlled_VBN trial_NN [_NN 17_CD ]_NN ._.
      
      
        Conclusions_NNP
        We_PRP found_VBD that_IN approximately_RB one-third_NN of_IN women_NNS with_IN
        normal_JJ ovarian_NN function_NN have_VBP ovarian_NN autoantibodies_NNS
        detected_VBN by_IN indirect_JJ immunofluorescence_NN using_VBG monkey_NN ovary_JJ
        as_IN substrate_NN ._. Hence_RB ,_, this_DT ovarian_NN antibody_NN test_NN as_RB
        presently_RB performed_VBN has_VBZ poor_JJ specificity_NN ,_, and_CC therefore_RB
        appears_VBZ to_TO have_VB no_DT benefit_NN in_IN the_DT evaluation_NN and_CC management_NN
        of_IN autoimmune_JJ premature_JJ ovarian_NN failure_NN ._. The_DT specificity_NN of_IN
        any_DT ovarian_NN antibody_NN test_NN should_MD be_VB established_VBN before_IN it_PRP
        is_VBZ used_VBN clinically_RB ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        J_NNP ._. A_DT ._. N_NNP ._. and_CC Z-B_NNP ._. T_NN ._. participated_VBD in_IN the_DT design_NN of_IN the_DT
        study_NN and_CC carried_VBD out_RP the_DT laboratory_NN investigation_NN ._. All_DT
        authors_NNS participated_VBD in_IN the_DT analysis_NN of_IN the_DT data_NNS and_CC the_DT
        preparation_NN of_IN the_DT manuscript_NN ._. L_NNP ._. M_NNP ._. N_NNP ._. conceived_VBD the_DT study_NN ,_,
        participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ,_, recruited_VBD the_DT
        patients_NNS ,_, and_CC was_VBD responsible_JJ for_IN their_PRP$ evaluation_NN and_CC
        clinical_JJ care_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ
        manuscript_NN ._.
      
    
  
